Ceradon
(Cefotiam)PreclinicalSmall molecule
TakedaCeradon is one of 4 small molecule programs targeting Gastric Varices. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
3
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Gastric Varices
#DrugCompanyPhaseTrials
1Inderal
WWyeth-Lederle Vaccines
Approved
Octreotide
Johnson & JohnsonPreclinical
Ceradon
TakedaPreclinical
Lauromacrogol
WWest China Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Dec 30, 1988
CERADON
NDA NDA050601
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cefotiam. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]